LONDON (Reuters) - ImClone Systems (IMCL.O: Quote, Profile, Research) shares soared nearly 30 percent in premarket trade on Tuesday on news Erbitux improves overall survival in lung cancer, offsetting earlier doubts about the drug's value in treating the disease.
O biotech firmama je bilo riječ na ovom blogu. Na žalost, nisam bio u IMCL-u prije objave.
Post je objavljen 11.09.2007. u 15:55 sati.